iPSC-based Respiratory Disease Modeling

Precision medicine has been rapidly developed in recent years. Creative Bioarray is focused on developing iPSC-based respiratory disease models in vitro to help our clients understand the pathophysiology of the human lung. Our significant advances in the field of cell reprogramming allow us to provide specialized solutions for researchers in the field of human lung research and autologous cell therapy.

iPSC for Modeling Respiratory Disease

Chronic respiratory disease (CRD) has received less attention than other non-communicable diseases. In recent years, the epidemic of coronavirus pneumonia (COVID-19) has added to the enormous socioeconomic burden caused by lung diseases. This has intensified the need for interventional treatments that can reduce organ damage, slow disease progression, and contribute to functional tissue recovery. To treat lung diseases and assess the potentially toxic effects of pollutant exposure, it is critical to develop organotypic models of the lung that accurately represent the physiology and anatomy of the lung under in vivo homeostatic and pathological conditions.

Extensive studies of lung disease have typically been conducted using animal models, but in vivo studies are difficult to translate into clinical outcomes due to the inherent disparity between lung function and tissue organization in humans and animals. Recent developments in iPSCs technologies have accelerated the generation of in vitro human lung models that facilitate large-scale pharmacological and toxicological screening. Importantly, the creation of lung models with different individual patient genetic backgrounds has helped to identify effective therapies tailored to each specific clinical situation, advancing the progress of personalized medicine.

Fig 1. Applications of iPSCs in in vitro lung modeling and precision medicine.Fig.1 Applications of iPSCs in in vitro lung modeling and precision medicine. (Moreira, 2021)

Our Solutions

Creative Bioarray has made great achievements in the application of iPSC technology to lung research. We not only develop iPSC-based lung models as test systems for toxicological research, but also help customers develop specific disease models derived from iPSCs for the development of personalized therapies. We provide customers with the following solutions:

  • Differentiation of iPSC into lung-specific cell types such as airway epithelium, alveolar epithelium, vascular system, and alveolar macrophages.
  • Establishment of iPSC-based lung models, including 2D approaches such as submerged or ALI monolayers, and 3D models including organoid, decellularized ECM-based models and lung-on-a-chip devices.
  • Establishment of iPSC-based lung diseases models, such as pulmonary fibrosis disease including idiopathic pulmonary fibrosis, cystic fibrosis and Hermansky–Pudlak syndrome, infectious diseases, and lung cancer.


  • Developmental studies
  • Assessing the potentially toxic effects of pollutant exposure and new therapeutic compounds
  • Basic research or pharmacological screening in drug development


  • Flexible solutions
  • Professional research teams
  • High-quality services
  • Cost-effectiveness

With an advanced cell reprogramming technology platform, Creative Bioarray provides clients with scientific and rational solutions and professional technical support in iPSC-based modeling of respiratory diseases. Please contact us if you are interested and we look forward to contributing to your research.


  1. Moreira, A.; et al. Advanced in vitro lung models for drug and toxicity screening: the promising role of induced pluripotent stem cells. Advanced Biology. 2021: 2101139.
For Research Use Only. Not For Clinical Use.